<DOC>
	<DOCNO>NCT00736775</DOCNO>
	<brief_summary>This Phase I , multicenter , randomize , double-blind , placebo-controlled study conduct United States consist single ascending-dose stage follow multidose , parallel-treatment stage . This study conduct approximately 50 adult patient 50-85 year old mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetics , Pharmacodynamics , Immunogenicity Anti-Abeta ( MABT5102A ) Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable AD accord NINCDSADRDA Criteria Approved AD treatment ( AchE inhibitors+/memantine ) must stable ≥ 3 month prior screen Other prescription medication must stable ≥ 1 month prior screen Female patient reproductive potential History presence clinically significant CNS disease History treatment protein therapeutic targeting Abeta</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>AD</keyword>
	<keyword>Alzheimer 's</keyword>
	<keyword>Alzheimers</keyword>
</DOC>